Curavit aiming to help developers prove the real-world value of digital therapeutics
Curavit Clinical Research has moved into health economics and outcomes analysis services with the aim of helping “digital therapeutics” developers win over the healthcare sector.
The clinical research organization (CRO) launched its Health Economics and Outcomes Research (HEOR) practice last week, with CEO and founder Joel Morse citing growing demand from the healthcare sector for ways to prove the value of drug products as a motivation.
"Payers are concerned with health outcomes and cost-effectiveness, especially as healthcare costs keep rising and when it comes to less-understood digital therapeutics,” he said, adding that developers of digital therapies would be a focus.
"We are helping DTx companies by seamlessly incorporating HEOR into their clinical trials, enabling them to not only capture safety and efficacy data but also financial data. The goal is that this information will prompt broader insurance coverage and use for patients in need. Digital medicines are here – let's streamline the steps required to prescribe and implement them."
Digital therapies (DTx) are a new category of treatments in which evidence-based therapeutic interventions driven by software to prevent, manage, or treat a medical disorder or disease.
Patient access
Medrhythms is using the service to assess the long-term patient adherence, response durability, and healthcare economic value of its novel neurorehabilitation system to improve walking in adults with chronic stroke walking deficits in a trial called OrcHESTRAS.
And the approach is working according to Medrhythms president and co-founder, Owen McCarthy, who said it is helping ensure patients can access the firm’s therapies.
“In conjunction with clinical outcomes, HEOR assessments are an indispensable part of the evidence package needed to 'speak the same language' with payers and gain traction with a new prescription-only product,” McCarthy said.
Real-world data
The ability to collect real-world evidence is particularly important for developers of DTx according to Andy Molnar, CEO of the Digital Therapeutics Alliance (DTA), an industry group that counts Curavit as a member.
"Real-world evidence is critical for DTx companies to achieve coverage and reimbursement by demonstrating to payors and providers the full impact of these innovations. Curavit's HEOR services will produce the real-world data needed to unlock wider insurance coverage and availability for transformative digital treatments.
Their decentralized trials rigorously demonstrating improved outcomes and reduced costs will be instrumental to driving comprehensive adoption of these breakthrough therapies," Molnar said.
DepositPhotos/ra2studio